KR970025611A - 치환된 설폰이미다미드, 이의 제조방법,약제 또는 진단제로서의 이의 용도 및 이를 함유하는 약제 - Google Patents

치환된 설폰이미다미드, 이의 제조방법,약제 또는 진단제로서의 이의 용도 및 이를 함유하는 약제 Download PDF

Info

Publication number
KR970025611A
KR970025611A KR1019960051506A KR19960051506A KR970025611A KR 970025611 A KR970025611 A KR 970025611A KR 1019960051506 A KR1019960051506 A KR 1019960051506A KR 19960051506 A KR19960051506 A KR 19960051506A KR 970025611 A KR970025611 A KR 970025611A
Authority
KR
South Korea
Prior art keywords
alkyl
group
carbon atoms
substituted
methyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1019960051506A
Other languages
English (en)
Korean (ko)
Inventor
하인츠-베르너 클레만
요아힘 브렌델
얀-로베르트 슈바르크
안드레아스 바이헤르트
한스-요헨 랑
우도 알부스
볼프강 숄츠
Original Assignee
야코비, 루츠
훽스트 아크티엔게젤샤프트
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 야코비, 루츠, 훽스트 아크티엔게젤샤프트 filed Critical 야코비, 루츠
Publication of KR970025611A publication Critical patent/KR970025611A/ko
Ceased legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C381/00Compounds containing carbon and sulfur and having functional groups not covered by groups C07C301/00 - C07C337/00
    • C07C381/10Compounds containing sulfur atoms doubly-bound to nitrogen atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/02Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/04Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/06Antiarrhythmics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/08Vasodilators for multiple indications
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Pulmonology (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Surgery (AREA)
  • Reproductive Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
KR1019960051506A 1995-11-03 1996-11-01 치환된 설폰이미다미드, 이의 제조방법,약제 또는 진단제로서의 이의 용도 및 이를 함유하는 약제 Ceased KR970025611A (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19540995.7 1995-11-03
DE19540995A DE19540995A1 (de) 1995-11-03 1995-11-03 Substituierte Sulfonimidamide, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament

Publications (1)

Publication Number Publication Date
KR970025611A true KR970025611A (ko) 1997-06-24

Family

ID=7776535

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019960051506A Ceased KR970025611A (ko) 1995-11-03 1996-11-01 치환된 설폰이미다미드, 이의 제조방법,약제 또는 진단제로서의 이의 용도 및 이를 함유하는 약제

Country Status (30)

Country Link
US (1) US5708034A (enExample)
EP (1) EP0771788B1 (enExample)
JP (1) JP3924028B2 (enExample)
KR (1) KR970025611A (enExample)
CN (1) CN1069312C (enExample)
AR (1) AR004253A1 (enExample)
AT (1) ATE188688T1 (enExample)
AU (1) AU707256B2 (enExample)
BR (1) BR9605417A (enExample)
CA (1) CA2189221C (enExample)
CZ (1) CZ290811B6 (enExample)
DE (2) DE19540995A1 (enExample)
DK (1) DK0771788T3 (enExample)
ES (1) ES2143122T3 (enExample)
GR (1) GR3032689T3 (enExample)
HR (1) HRP960496B1 (enExample)
HU (1) HUP9603023A3 (enExample)
IL (1) IL119552A (enExample)
MX (1) MX9605317A (enExample)
MY (1) MY132862A (enExample)
NO (1) NO306550B1 (enExample)
NZ (1) NZ299682A (enExample)
PL (1) PL184570B1 (enExample)
PT (1) PT771788E (enExample)
RU (1) RU2180658C2 (enExample)
SI (1) SI0771788T1 (enExample)
SK (1) SK281766B6 (enExample)
TR (1) TR199600873A2 (enExample)
TW (1) TW352382B (enExample)
ZA (1) ZA969211B (enExample)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19820064A1 (de) * 1998-05-06 1999-11-11 Hoechst Marion Roussel De Gmbh Substituierte Sulfonylcyanamide, Verfahren zu ihrer Herstellung und ihre Verwendung als Medikament
DE19832428A1 (de) * 1998-07-18 2000-01-20 Hoechst Marion Roussel De Gmbh Imidazolderivate mit Biphenylsulfonylsubstitution, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament
DE19832429A1 (de) * 1998-07-18 2000-01-20 Hoechst Marion Roussel De Gmbh Imidazolderivate mit Biphenylsulfonylsubstitution, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament
KR101699822B1 (ko) 2011-12-21 2017-01-25 노비라 테라퓨틱스, 인코포레이티드 B형 간염의 항바이러스성 제제
AR092269A1 (es) 2012-08-28 2015-04-08 Janssen R&D Ireland Sulfamoilarilamidas y su uso como medicamentos para el tratamiento de la hepatitis b
SI2961732T1 (sl) 2013-02-28 2017-07-31 Janssen Sciences Ireland Uc Sulfamoil-arilamidi in njihova uporaba kot zdravila za zdravljenje hepatitisa B
HUE033542T2 (en) 2013-04-03 2017-12-28 Janssen Sciences Ireland Uc Their use as medicaments for the treatment of N-phenylcarboxamide derivatives and hepatitis B
JO3603B1 (ar) 2013-05-17 2020-07-05 Janssen Sciences Ireland Uc مشتقات سلفامويل بيرولاميد واستخدامها كادوية لمعالجة التهاب الكبد نوع بي
US10160743B2 (en) 2013-05-17 2018-12-25 Janssen Sciences Ireland Uc Sulphamoylthiophenamide derivatives and the use thereof as medicaments for the treatment of hepatitis B
SG10201805033XA (en) 2013-07-25 2018-07-30 Janssen Sciences Ireland Uc Glyoxamide substituted pyrrolamide derivatives and the use thereof as medicaments for the treatment of hepatitis b
JP6452119B2 (ja) 2013-10-23 2019-01-16 ヤンセン・サイエンシズ・アイルランド・アンリミテッド・カンパニー カルボキサミド誘導体およびb型肝炎の処置のための医薬品としてのその使用
US10392349B2 (en) 2014-01-16 2019-08-27 Novira Therapeutics, Inc. Azepane derivatives and methods of treating hepatitis B infections
US9169212B2 (en) 2014-01-16 2015-10-27 Novira Therapeutics, Inc. Azepane derivatives and methods of treating hepatitis B infections
JP6553059B2 (ja) 2014-02-05 2019-07-31 ノヴィラ・セラピューティクス・インコーポレイテッド Hbv感染の治療のための併用療法
US11078193B2 (en) 2014-02-06 2021-08-03 Janssen Sciences Ireland Uc Sulphamoylpyrrolamide derivatives and the use thereof as medicaments for the treatment of hepatitis B
CA2980298A1 (en) 2015-03-19 2016-09-22 Novira Therapeutics, Inc. Azocane and azonane derivatives and methods of treating hepatitis b infections
US10875876B2 (en) 2015-07-02 2020-12-29 Janssen Sciences Ireland Uc Cyclized sulfamoylarylamide derivatives and the use thereof as medicaments for the treatment of hepatitis B
CN108430971A (zh) 2015-09-29 2018-08-21 诺维拉治疗公司 乙型肝炎抗病毒剂的晶体形式
BR112018071048A2 (pt) 2016-04-15 2019-05-07 Janssen Sciences Ireland Uc combinações e métodos que compreendem um inibidor da montagem de capsídeos
CN110248628A (zh) * 2017-01-31 2019-09-17 宝洁公司 成型的非织造织物和包括所述织物的制品
EP3644930A1 (en) 2017-06-30 2020-05-06 The Procter and Gamble Company Shaped nonwoven
US10577722B2 (en) 2017-06-30 2020-03-03 The Procter & Gamble Company Method for making a shaped nonwoven
BR112020018601A2 (pt) 2018-03-14 2020-12-29 Janssen Sciences Ireland Unlimited Company Regime de dosagem de modulador de montagem de capsídeo
KR20210034596A (ko) 2018-07-20 2021-03-30 에프. 호프만-라 로슈 아게 인터류킨-1 활성의 저해제로서 술폰이미드아미드 화합물
AU2020223865A1 (en) 2019-02-22 2021-07-15 Janssen Sciences Ireland Unlimited Company Amide derivatives useful in the treatment of HBV infection or HBV-induced diseases
GB2596718A (en) 2019-03-18 2022-01-05 Procter & Gamble Shaped nonwovens that exhibit high visual resolution
TW202108576A (zh) 2019-05-06 2021-03-01 愛爾蘭商健生科學愛爾蘭無限公司 用於治療hbv感染或hbv誘發的疾病之醯胺衍生物
CN116492469A (zh) * 2023-05-22 2023-07-28 遵义医科大学附属医院 一种通道阻滞剂在制备治疗和/或预防肝纤维疾病药物中的应用

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5091394A (en) * 1989-09-06 1992-02-25 Hoechst Aktiengesellschaft Benzoylguanidines, a process for their preparation, their use as medicaments and medicaments containing them
JPH0776566A (ja) * 1993-08-13 1995-03-20 Hoechst Ag 尿素置換ベンゾイルグアニジン、その製造方法、医薬または診断剤としてのその使用およびそれを含有する医薬
KR960029320A (ko) * 1995-01-30 1996-08-17 로제르트·루츠 염기성 치환된 벤조일구아니딘, 이의 제조방법, 약제 또는 진단제로서의 이의 용도 및 이를 함유하는 약제
US5569674A (en) * 1992-07-21 1996-10-29 Ciba-Geigy Corporation Heteroacetic acid derivatives

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3780027A (en) * 1970-04-29 1973-12-18 Merck & Co Inc Anthranilic acid derivatives
US5140039A (en) * 1988-01-15 1992-08-18 Abbott Laboratories Aminomethyl-thiochroman compounds
US5185364A (en) * 1988-01-15 1993-02-09 Abbott Laboratories Aminomethyl-chroman and -thiochroman compounds
EP0396620B1 (en) * 1988-01-15 1993-08-11 Abbott Laboratories Aminomethyl-chroman and -thiochroman compounds
DE4010325A1 (de) * 1989-04-03 1990-10-04 Ciba Geigy Ag Neue carbaminsaeureester
US5140026A (en) * 1991-05-09 1992-08-18 A. H. Robins Company, Incorporated N-aminoalkyl-S-aryl-S-alkyl (or substituted alkyl) sulfoximines as antiarrhythmic agents
CZ284456B6 (cs) * 1992-02-15 1998-12-16 Hoechst Aktiengesellschaft Aminosubstituované benzoylguanidiny, způsob jejich přípravy, jejich použití jako léčiv a léčivo, které je obsahuje
DE59307360D1 (de) * 1992-02-15 1997-10-23 Hoechst Ag Ortho-substituierte Benzoylguanidine, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament
EP0556674B1 (de) * 1992-02-15 1996-06-19 Hoechst Aktiengesellschaft 3,5-Substituierte Benzoylguanidine, mit antiarrythmischer Wirkung und inhibierender Wirkung auf die Proliferationen von Zellen
ATE144248T1 (de) * 1992-07-01 1996-11-15 Hoechst Ag 3,4,5-substituierte benzoylguanidine, verfahren zu ihrer herstellung, ihre verwendung als medikament oder diagnostikum sowie sie enthaltendes medikament
ES2097409T3 (es) * 1992-09-22 1997-04-01 Hoechst Ag Benzoilguanidinas, procedimiento para su preparacion, asi como su empleo como antiarritmicos.
DE69329787T2 (de) * 1992-09-28 2001-06-13 Hoechst Ag Antiarrhythmische und cardioprotektive substituierte 1(2H)-Isochinoline, Verfahren zu deren Herstellung, diese enthaltende Arzneimittel und ihre Anwendung für die Herstellung eines Arzneimittels zur Behandlung von Herzinsuffizienzen
DE59309360D1 (de) * 1992-12-02 1999-03-18 Hoechst Ag Guanidinalkyl-1, 1-bisphosphonsäurederivate, Verfahren zu ihrer Herstellung und ihre Verwendung
TW250477B (enExample) * 1992-12-15 1995-07-01 Hoechst Ag
TW250479B (enExample) * 1992-12-15 1995-07-01 Hoechst Ag
DE59306029D1 (de) * 1992-12-16 1997-05-07 Hoechst Ag 3,5-Substituierte Aminobenzoylguanidine, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament
EP0604852A1 (de) * 1992-12-28 1994-07-06 Hoechst Aktiengesellschaft 2,4-Substituierte 5-(N-substituierte-Sulfamoyl)-Benzoylguanidine, als Antiarrythmika, Inhibitoren der Proliferationen von Zellen, und Inhibitoren des Natrium-Protonen-Antiporters
ES2107698T3 (es) * 1993-02-20 1997-12-01 Hoechst Ag Benzoilguanidinas sustituidas, procedimiento para su preparacion, su utilizacion como medicamento, como inhibidores del intercambio celular de na+/h+ o como agente de diagnostico, asi como medicamento que las contiene.
DK0612724T3 (da) * 1993-02-23 1997-06-16 Hoechst Ag Substituerede benzensulfonylurinstoffer og -thiourinstoffer, fremgangsmåde til deres fremstilling og deres anvendelse som farmaceutika
IL109570A0 (en) * 1993-05-17 1994-08-26 Fujisawa Pharmaceutical Co Guanidine derivatives, pharmaceutical compositions containing the same and processes for the preparation thereof
DE4318658A1 (de) * 1993-06-04 1994-12-08 Hoechst Ag Substituierte Benzoylguanidine, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament
DE4318756A1 (de) * 1993-06-05 1994-12-08 Hoechst Ag Substituierte Benzoylguanidine, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament
DE4325822A1 (de) * 1993-07-31 1995-02-02 Hoechst Ag Substituierte Benzoylguanidine, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament
EP0639573A1 (de) * 1993-08-03 1995-02-22 Hoechst Aktiengesellschaft Benzokondensierte 5-Ringheterocyclen, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament, ihre Verwendung als Diagnostikum, sowie sie enthaltendes Medikament
DE4328869A1 (de) * 1993-08-27 1995-03-02 Hoechst Ag Ortho-substituierte Benzoylguanidine, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament
DE4344550A1 (de) * 1993-12-24 1995-06-29 Hoechst Ag Substituierte 1-Oxo-1,2-dihydro-isochinolinoyl- und 1,1-Dioxo-2H-1,2-benzothiazinoylguanidine, Verfahrenzu ihrer Herstellung, ihre Verwendung als Medikamentt oder Diagnostikum sowie sie enthaltendes Medikamen
TW415937B (en) * 1994-01-25 2000-12-21 Hoechst Ag Phenyl-substituted alkylcarboxylic acid guanidides bearing perfluoroalkyl groups, process for their preparation, their use as a medicament or diagnostic, and medicament containing them
DE4412334A1 (de) * 1994-04-11 1995-10-19 Hoechst Ag Substituierte N-Heteroaroylguanidine, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament
DE4415873A1 (de) * 1994-05-05 1995-11-09 Hoechst Ag Substituierte bizyklische Heteroaroylguanidine, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament
DE4417004A1 (de) * 1994-05-13 1995-11-16 Hoechst Ag Perfluoralkyl-substituierte Benzoylguanidine, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament
DE4422685A1 (de) * 1994-06-29 1996-01-04 Hoechst Ag Ortho-amino-substituierte Benzoylguanidine, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament
IL114670A0 (en) * 1994-08-05 1995-11-27 Fujisawa Pharmaceutical Co Guanidine derivatives pharmaceutical compositions containing the same and processes for the preparation thereof
DE4432106A1 (de) * 1994-09-09 1996-03-14 Hoechst Ag Mit Heterocyclen-N-Oxid-substituierte Benzoylguanidine, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum, sie enthaltendes Medikament sowie Zwischenprodukte zu ihrer Herstellung
DE4432105A1 (de) * 1994-09-09 1996-03-14 Hoechst Ag Fluoro-alkyl/alkenyl-substituierte Benzoylguanidine, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament
DE4432101A1 (de) * 1994-09-09 1996-03-14 Hoechst Ag Aminosäure-substituierte Benzoylguanidine, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament
DE4441880A1 (de) * 1994-11-24 1996-05-30 Hoechst Ag Substituierte Benzoylguanidine, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5091394A (en) * 1989-09-06 1992-02-25 Hoechst Aktiengesellschaft Benzoylguanidines, a process for their preparation, their use as medicaments and medicaments containing them
US5569674A (en) * 1992-07-21 1996-10-29 Ciba-Geigy Corporation Heteroacetic acid derivatives
JPH0776566A (ja) * 1993-08-13 1995-03-20 Hoechst Ag 尿素置換ベンゾイルグアニジン、その製造方法、医薬または診断剤としてのその使用およびそれを含有する医薬
KR960029320A (ko) * 1995-01-30 1996-08-17 로제르트·루츠 염기성 치환된 벤조일구아니딘, 이의 제조방법, 약제 또는 진단제로서의 이의 용도 및 이를 함유하는 약제

Also Published As

Publication number Publication date
TR199600873A2 (tr) 1997-05-21
SK281766B6 (sk) 2001-07-10
AU7060896A (en) 1997-05-08
CA2189221C (en) 2006-10-03
PT771788E (pt) 2000-05-31
CA2189221A1 (en) 1997-05-04
CN1069312C (zh) 2001-08-08
CZ290811B6 (cs) 2002-10-16
HRP960496B1 (en) 2000-12-31
SK141896A3 (en) 1997-06-04
NO964639L (no) 1997-05-05
EP0771788B1 (de) 2000-01-12
IL119552A (en) 2000-09-28
HUP9603023A3 (en) 1998-12-28
ES2143122T3 (es) 2000-05-01
PL184570B1 (pl) 2002-11-29
PL316440A1 (en) 1997-05-12
GR3032689T3 (en) 2000-06-30
CZ318496A3 (en) 1997-05-14
HU9603023D0 (en) 1996-12-30
DE19540995A1 (de) 1997-05-07
RU2180658C2 (ru) 2002-03-20
NO306550B1 (no) 1999-11-22
MY132862A (en) 2007-10-31
EP0771788A3 (de) 1997-09-03
HRP960496A2 (en) 1998-02-28
DK0771788T3 (da) 2000-06-13
CN1155538A (zh) 1997-07-30
TW352382B (en) 1999-02-11
AR004253A1 (es) 1998-11-04
ATE188688T1 (de) 2000-01-15
AU707256B2 (en) 1999-07-08
BR9605417A (pt) 1998-08-04
ZA969211B (en) 1997-05-03
DE59604165D1 (de) 2000-02-17
SI0771788T1 (en) 2000-04-30
MX9605317A (es) 1997-05-31
US5708034A (en) 1998-01-13
HUP9603023A2 (hu) 1998-01-28
NZ299682A (en) 1997-07-27
NO964639D0 (no) 1996-11-01
JPH09169723A (ja) 1997-06-30
JP3924028B2 (ja) 2007-06-06
IL119552A0 (en) 1997-02-18
EP0771788A2 (de) 1997-05-07

Similar Documents

Publication Publication Date Title
KR970025611A (ko) 치환된 설폰이미다미드, 이의 제조방법,약제 또는 진단제로서의 이의 용도 및 이를 함유하는 약제
RU2002101723A (ru) Инданилзамещенные бензолкарбонамиды, способ их получения, их применение в качестве лекарственного средства, а также содержащие их фармацевтические композиции
KR950005817A (ko) 5원환을 갖는 벤조-융합된 헤테로사이클릭 화합물, 이의 제조방법, 약제로서의 이의 용도, 진단제로서의 이의 용도 및 이를 함유하는 약제
JPH09169723A5 (enExample)
RU96121572A (ru) Сульфонимидамиды, способ их получения, фармацевтический состав, способ его получения, способ лечения
ATE19878T1 (de) Benzimidazol-derivate, verfahren zu deren herstellung und diese enthaltende pharmazeutische zusammensetzungen.
KR900003151A (ko) 화합물
KR960000861A (ko) 퍼플루오로알킬 그룹을 갖는 페닐-치환된 알케닐카보구아니디드, 이의 제조방법, 약제 또는 진단제로서의 이의 용도 및 이를 함유하는 약제
KR950010892A (ko) 자궁 섬유증 억제 방법
NO934634L (no) 3,5-substiturete aminobenzoylguanidiner, fremgangsmåte til fremstilling derav, deres anvendelse som medikament eller diagnostikum samt middel inneholdende forbindelsene
KR910011812A (ko) 염증성 장 질환 치료용 화합물
KR960007592A (ko) 신규한 피롤로카바졸
RU96109699A (ru) Гуанидиды алкенилкарбоновых кислот, способ их получения, содержащее их лекарственное или диагностическое средство, способ его получения, способ лечения и профилактики сердечных заболеваний
KR970074776A (ko) 치환된 2-나프토일구아니딘, 이의 제조방법, 약물 또는 진단제로서의 이의 용도 및 이를 함유하는 약제
KR960010618A (ko) 아미노산 치환된 벤조일구아니딘, 이의 제조방법, 약제 또는 진단제로서의 이의 용도 및 이를 함유하는 약제
RU97109003A (ru) Замещенные 2-нафтоилгуанидины, способ их получения и лекарственное средство на их основе
KR970015568A (ko) 치환된 벤조일구아니딘, 이의 제조방법, 약제 또는 진단제로서의 이의 용도 및 이를 포함하는 약제
KR970006282A (ko) 4-플루오로알킬-치환된 벤조일구아니딘, 이의 제조방법, 약제 또는 진단제로서의 이의 용도, 및 이를 포함하는 약제
KR970026597A (ko) 설포닐아미노-치환된 벤조일구아니딘, 이의 제조 방법, 약제 또는 진단 보조제로서의 이의 용도 및 이를 함유하는 약제
KR980002019A (ko) 오르토-치환된 벤조일구아니딘, 이의 제법, 약제 또는 진단제로서의 이의 용도 및 이를 포함하는 약제
KR890012942A (ko) 5-치환된 오르니틴 유도체
RU97109002A (ru) Замещенные 1-нафтоилгуанидины, способ их получения и лекарственное средство на их основе
JPH1081663A5 (enExample)
ATE34739T1 (de) Neue 2-pyridin-thiol-derivate, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische praeparate.
KR970061887A (ko) 치환된 티오페닐알케닐카복실산 구아니디드, 이의 제조방법, 약물 및 진단제로서의 이의 용도 및 이를 함유하는 약제

Legal Events

Date Code Title Description
PA0109 Patent application

Patent event code: PA01091R01D

Comment text: Patent Application

Patent event date: 19961101

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20011031

Comment text: Request for Examination of Application

Patent event code: PA02011R01I

Patent event date: 19961101

Comment text: Patent Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20040130

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20040420

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20040130

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I